13 January 2020 in Proceedings of the National Academy of Sciences
LCLieselot L. G. Carrette
+2
Significance: More than 2 million individuals in the United States currently have a substance use disorder that is related to prescription opioid pain relievers. We identified individual differences in oxycodone addiction-like behaviors in outbred heterogenous stock rats with high and low addiction-like behaviors. We found that the downregulation of nociceptin levels in the central nucleus of the amygdala (CeA) may be responsible for hyper–γ-aminobutyric acid (GABA)ergic tone in the CeA that is observed in individuals who develop addiction-like behaviors. The development of small molecules that target the nociceptin system may have therapeutic efficacy for the treatment of opioid use disorder.
29 February 2020 in Psychopharmacology
23 August 2017 in Alcohol, Clinical and Experimental Research
1 September 2017 in The Journal of Pharmacology and Experimental Therapeutics
Cebranopadol is a novel agonist of nociceptin/orphanin FQ peptide (NOP) and opioid receptors with analgesic properties that is being evaluated in clinical Phase 2 and Phase 3 trials for the treatment of chronic and acute pain. Recent evidence indicates that the combination of opioid and NOP receptor agonism may be a new treatment strategy for cocaine addiction. We sought to extend these findings by examining the effects of cebranopadol on cocaine self-administration (0.5 mg/kg/infusion) and cocaine conditioned reinstatement in rats with extended access to cocaine. Oral administration of cebranopadol (0, 25, and 50 μg/kg) reversed the escalation of cocaine self-administration in rats that were given extended (6 hour) access to cocaine, whereas it did not affect the self-administration of sweetened condensed milk (SCM). Cebranopadol induced conditioned place preference but did not affect locomotor activity during the conditioning sessions. Finally, cebranopadol blocked the conditioned reinstatement of cocaine seeking. These results show that oral cebranopadol treatment prevented addiction-like behaviors (i.e., the escalation of intake and reinstatement), suggesting that it may be a novel strategy for the treatment of cocaine use disorder. However, the conditioned place preference that was observed after cebranopadol administration suggests that this compound may have some intrinsic rewarding effects.
1 May 2016 in The Journal of Pharmacology and Experimental Therapeutics
The brain histamine system has been implicated in regulation of sensorimotor gating deficits and in Gilles de la Tourette syndrome (GTS). Histamine also regulates alcohol reward and consumption via H3 receptor (H3R), possibly through an interaction with the brain dopaminergic system. Here we identified the histaminergic mechanism of sensorimotor gating and the role of histamine H3R in the regulation of dopaminergic signaling. We found that H3R knockout mice displayed impaired prepulse inhibition (PPI) indicating deficiency in sensorimotor gating. H1R knockout and HDC knockout mice had similar PPI as their controls. Dopaminergic drugs increased PPI of H3R knockout mice to the same level as in control mice suggesting that changes in dopamine receptors might underlie deficient PPI response when H3R is lacking. Striatal D1R mRNA level was lower and D1 and D2 receptor-mediated activation of extracellular signal-regulated kinase 1/2 (ERK1/2) was absent in the striatum of H3R knockout mice suggesting that H3R is essential for the dopamine receptor-mediated signaling. In conclusion, these findings demonstrate that H3R is an important regulator of sensorimotor gating and the lack of H3R significantly modifies striatal dopaminergic signaling. These data support the usefulness of H3R ligands in neuropsychiatric disorders with pre-attentional deficits and disturbances in dopaminergic signaling.